Daniel Speidel

Daniel Speidel

Company: Breakpoint Therapeutics

Job title: Managing Director & Co- Founder

Seminars:

Chair’s Opening Remarks 8:25 am

Read more

day: Day One

Panel Discussion: What Makes the Perfect Next-Generation DDR Inhibitor Target? 4:30 pm

• How does protein size and function impact small molecule approaches? • Where does pathway redundancy fit into the journey of finding new targets? • Why have next generation targets been less successful moving through clinical phases?Read more

day: Day One

Chair’s Closing Remarks 5:00 pm

Read more

day: Day One

Chair’s Opening Remarks 8:50 am

Read more

day: Day Two

Chair’s Closing Remarks 4:00 pm

Read more

day: Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.